Quince Therapeutics (QNCX) Net Cash Flow (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Net Cash Flow of $13.8 million for Q1 2026, up 898.27% year-over-year from $1.4 million in Q1 2025, and up 3774.47% quarter-over-quarter from -$376000.0 in Q4 2025.
Quince Therapeutics (QNCX) Net Cash Flow (2018 - 2026) Analysis & Trends
Quince Therapeutics' Net Cash Flow history runs 9 years deep, the most recent figure standing at $13.8 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 898.27% year-over-year to $13.8 million; the TTM figure through Mar 2026 stood at $12.1 million (up 185.89% YoY), while the FY2025 annual figure was -$289000.0, up 98.04% from the prior year.
- Net Cash Flow for Q1 2026 stood at $13.8 million, up from -$376000.0 in the prior quarter.
- The five-year high for Net Cash Flow was $13.8 million in Q1 2026, with the low at -$24.1 million in Q2 2023.
- The 5-year median for Net Cash Flow is -$631000.0 (2023), against an average of -$3.0 million.
- The sharpest annual moves came in 2024 and 2026: Net Cash Flow slumped 339.47% in 2024, then surged 898.27% in 2026.
- Quince Therapeutics' Net Cash Flow stood at $12.8 million in 2022, then slumped by 104.92% to -$631000.0 in 2023, then jumped by 625.36% to $3.3 million in 2024, then plunged by 111.34% to -$376000.0 in 2025, then jumped by 3774.47% to $13.8 million in 2026.
- Business Quant data shows QNCX's Net Cash Flow at $13.8 million in Q1 2026, -$376000.0 in Q4 2025, and -$10.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - | 98.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.82 Mn |
| Mar 31, 2026 | 13.82 Mn |
| Dec 31, 2025 | -376,000.00 |
| Dec 31, 2025 | -376,000.00 |
| Sep 30, 2025 | -10.33 Mn |
| Sep 30, 2025 | -10.33 Mn |
| Jun 30, 2025 | 9.04 Mn |
| Jun 30, 2025 | 9.04 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Mar 31, 2025 | 1.38 Mn |
| Dec 31, 2024 | 3.32 Mn |
| Dec 31, 2024 | 3.32 Mn |
| Sep 30, 2024 | -5.16 Mn |
| Sep 30, 2024 | -5.16 Mn |
| Jun 30, 2024 | -13.68 Mn |
| Jun 30, 2024 | -13.68 Mn |
| Mar 31, 2024 | 751,000.00 |
| Mar 31, 2024 | 751,000.00 |
| Dec 31, 2023 | -631,000.00 |
| Dec 31, 2023 | -631,000.00 |